Durham, NC, United States of America

Christopher MacNevin

USPTO Granted Patents = 2 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2016-2020

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Christopher MacNevin in Neuroprotection**

Introduction

Christopher MacNevin, an accomplished inventor based in Durham, NC, has made significant strides in the field of neuroprotection through his innovative research and development. With a total of two patents to his name, MacNevin's work stands at the intersection of science and applied medicine, aiming to provide solutions for neurodegenerative conditions.

Latest Patents

MacNevin's latest patents focus on the development of steroid analogues specifically designed for neuroprotection. These analogues are characterized by their functionalization with polar substituents at the C3 and/or C20 positions of the steroid ring system. This unique modification enhances their water solubility, offering a promising avenue for pharmaceutical compositions targeting neurodegeneration. His innovative methods employ these novel steroid analogues to treat and prevent neurodegeneration in patients who have suffered injuries to the central nervous system.

Career Highlights

Currently affiliated with Emory University, Christopher MacNevin has been instrumental in advancing research that bridges fundamental science and clinical applications. His dedication to understanding neuroprotection has positioned him as a leading figure in his field, focusing on practical solutions aimed at improving patient outcomes.

Collaborations

Throughout his career, MacNevin has collaborated with notable peers such as Donald G. Stein and Dennis C. Liotta. These associations reflect a commitment to interdisciplinary research, pooling expertise to foster innovation in neuroprotection therapies.

Conclusion

Christopher MacNevin's contributions to neuroprotection through his patented steroid analogues demonstrate the potential for innovation in treating neurodegenerative conditions. As he continues to collaborate with esteemed professionals and contribute to impactful research, MacNevin’s work remains a beacon of hope in the quest for effective therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…